Endpoints for clinical trials in type 1 diabetes drug development.
Alfonso Galderisi, Brynn E Marks, Linda A DiMeglio, Carine de Beaufort
Author Information
- Alfonso Galderisi: Pediatric Endocrinology and Diabetes, Department of Pediatrics, Yale University, New Haven, CT, USA.
- Brynn E Marks: Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- Linda A DiMeglio: Division of Pediatric Endocrinology and Diabetology, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA.
- Carine de Beaufort: Diabetes & Endocrine Care Clinique P��diatrique, Clinique P��diatrique Centre Hospitalier de Luxembourg, 1210 Luxembourg City, Luxembourg; Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-Belval, Luxembourg. Electronic address: bcschim@pt.lu.
No abstract text available.
- Diabetes Care. 2022 Feb 1;45(2):311-318
[PMID: 34853027]
- Diabetologia. 2023 Dec;66(12):2189-2199
[PMID: 37712956]
- J Clin Endocrinol Metab. 2024 Jan 24;:
[PMID: 38267821]
- Diabetes Care. 2014 Apr;37(4):979-84
[PMID: 24550217]
- J Pediatr. 1989 Jun;114(6):963-7
[PMID: 2524556]
- Diabetes Care. 2015 Oct;38(10):1964-74
[PMID: 26404926]
- JAMA. 2023 Mar 28;329(12):990-999
[PMID: 36826844]
- J Clin Endocrinol Metab. 2023 Dec 21;109(1):57-67
[PMID: 37572381]
- K23 DK129827/NIDDK NIH HHS
- UL1 TR001863/NCATS NIH HHS
Humans
Clinical Trials as Topic
Diabetes Mellitus, Type 1
Drug Development
Endpoint Determination
Hypoglycemic Agents
